Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
25
03
2021
revised:
12
05
2021
accepted:
23
07
2021
pubmed:
29
7
2021
medline:
8
4
2022
entrez:
28
7
2021
Statut:
ppublish
Résumé
The multiple myeloma treatment landscape has evolved considerably over the last 20 years with the development of multiple therapies with novel mechanisms of action and new combination regimens. However, the recent failure of several large phase III trials, coupled with an increased understanding of the mutational landscape of multiple myeloma has provided opportunities to explore optimal strategies for future multiple myeloma drug development. The Office of Oncologic Diseases at the FDA held an educational symposium, "Drug Development in MM-Project 2025," in November 2019. The symposium brought together select U.S.-based academic thought leaders in the field of multiple myeloma to explore issues relevant to regulatory science in the field, including considerations for trial design, combination strategies, control arms, and precision medicine. This article summarizes the highlights of this educational symposium held at the FDA, including discussions on the future development of novel drugs and drug combinations and biomarker-directed therapies for patients with multiple myeloma.
Identifiants
pubmed: 34315721
pii: 1078-0432.CCR-21-1069
doi: 10.1158/1078-0432.CCR-21-1069
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-26Informations de copyright
©2021 American Association for Cancer Research.
Références
Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630–42.
Gormley NJ, Pazdur R. Immunotherapy combinations in multiple myeloma — known unknowns. N Engl J Med. 2018;379:1791–5.
Kumar S, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AA, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. J Clin Oncol. 2020.
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial. Lancet Haematol. 2020;7:e3370–380.
Stewart K, Rajkumar V, Dimopoulos M, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Eng J Med. 2015;372:142–52.